Kyungpook National University Industry-Academic Cooperation Foundation;Korea Institute of Science and Technology
发明人:
申请号：
EP18736762.8
公开号：
EP3567048A1
申请日:
2018.01.04
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
The present invention relates to: a fusion peptide comprising a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide； and a use thereof and, more specifically, to: a fusion peptide in which a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide are sequentially linked； a composition for preventing or treating thrombotic disorders, containing the same as an active ingredient； a method for treating thrombotic disorders； and a therapeutic use. According to the present invention, CLT-sFt-µPn DCNC as a novel plasmin-based thrombolytic nanocage has: an effect of targeting a site at which thrombus is present； a low sensitivity to inhibitors present in the circulatory system； pharmacological activity strongly destroying both arterial and venous thrombi； and no side effects of bleeding, and thus can be very useful in developing an agent for preventing or treating thrombotic disorders.
